Non-surgical back of eye disease treatment trialled

Article

The Phase III trial of microplasmin for the treatment of back of the eye disease has been initiated, according to a statement from ThromboGenics NV, the developer of microplasmin.

The Phase III trial of microplasmin for the treatment of back of the eye disease has been initiated, according to a statement from ThromboGenics NV, the developer of microplasmin.

The multicentre MIVI-TRUST (Microplasmin for IntraVitreous Injection-Traction Release without Surgical Treatment) trial will be conducted in Europe and North America, and will evaluate microplasmin versus placebo as an intravitreal treatment of patients with focal vitreomacular adhesion. Approximately 80 centres will enrol approximately 320 patients each, and the primary endpoint is resolution of vitreomacular adhesion at one month.

The studies, which were initiated following promising Phase II results, are planned to be completed by the end of 2010.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.